Fanskya (Mozafancogene autotemcel)
OrphanPRIMEATMP
- Region
- 🇪🇺 EU
- Active substance
- Mozafancogene autotemcel
- Company
- Rocket Pharmaceuticals B.V.
- Status
- Application withdrawn
- Therapeutic area
- Fanconi Anemia
- Designations
- Orphan, PRIME, ATMP
- Application
- EMEA/H/C/005537
- Official record
- www.ema.europa.eu
Indication
Treatment of paediatric patients with Fanconi Anaemia Type A
Regulatory milestones
No milestones recorded in the last year.
Follow Fanskya
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.